文章摘要
宋永波,赵璐,杜小明,等.阿帕替尼治疗晚期乳腺癌20例[J].安徽医药,2019,23(8):1670-1673.
阿帕替尼治疗晚期乳腺癌20例
Apatinib's clinical observation of 20 cases in advanced breast cancer
投稿时间:2018-01-18  
DOI:
中文关键词: 乳腺肿瘤  血管内皮生长因子受体2  分子靶向治疗  阿帕替尼  治疗结果
英文关键词: Breast neoplasms  Vascular endothelial growth factor receptor-2  Molecular targeted therapy  Apatinib  Treatment outcome
基金项目:
作者单位
宋永波 皖北煤电集团总医院肿瘤一科,安徽 宿州 234000  
赵璐 皖北煤电集团总医院肿瘤一科,安徽 宿州 234000  
杜小明 皖北煤电集团总医院肿瘤一科,安徽 宿州 234000  
张长永 宿州市立医院肿瘤内科,安徽 宿州 234000  
曹玉文 石河子大学医学院,新疆维吾尔自治区 石河子 832000 
摘要点击次数: 49
全文下载次数: 45
中文摘要:
      目的 研究阿帕替尼治疗晚期乳腺癌的临床疗效及预后。方法 2015年5月至2017年6月皖北煤电集团总医院及宿州市立医院经病理学确诊的44例乳腺癌病人中20例口服阿帕替尼,24例行姑息对症支持治疗,比较两组总生存期、无进展生存期、疗效及对口服阿帕替尼不良反应的观察。结果 阿帕替尼组病人的中位总生存期(14个月)及中位无进展生存期(11个月)均长于姑息治疗组(6个月,4个月),两组差异有统计学意义(Kaplan-Meier法,P<0.05);阿帕替尼组病人的疾病控制率(85%)远高于姑息治疗组(46%),两组差异有统计学意义(χ2 =14.204,P=0.003);口服阿帕替尼治疗中,不良反应多为1[KG-*3]~2级,治疗过程中无因为不能耐受不良反应而停止阿帕替尼靶向治疗。结论 阿帕替尼治疗一线、二线及三线治疗失败的晚期乳腺癌有较好的临床疗效及生存获益,不良反应可控制,值得临床上广泛应用。
英文摘要:
      Objective To evaluate the prognosis and efficacy of Apatinib in advanced breast cancer patients.Methods 44 patients with pathologically confirmed advanced breast cancer in the General Hospital of Anhui Coal Power and Suzhou Municipal Hospital from May 2015 to June 2017 were divided into two groups,20 patients were treated with Apatinib and 24 patients were treated with palliative care.Clinical efficacy and adverse reactions were observed,Kaplan-Meier method was used for survival analysis.Results Median total survival (14 months) and median progression-free survival (11 months) were longer in the Apatinib group than in the palliative care group (6 months,4 months),and the difference between the two groups was statistically significant (P<0.05).The disease control rate (85%) of the Apatinib group was significantly higher than that in palliative care group (46%),and the difference between the two groups was statistically significant (χ2=14.204,P=0.003).When patients took Apatinib,the adverse reaction occurred in most patients at the 1-2 level,and no patients stopped treatment because they couldn't tolerate the adverse reactions.Conclusion Administration of Apatinib in advanced breast cancer patients after failure of first-line or beyond treatment is still beneficial in terms of higher disease control rate and better survival,and adverse reactions are tolerable.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮